SSRIs and Sexual Side Effects in Men: Delayed Ejaculation, Numbness, and PSSD

Sexual side effects affect an estimated 25-73% of men on SSRIs depending on the specific medication and study methodology, making it one of the most common — and most underreported — adverse effects in psychiatric medicine [1]. The mechanism is well understood: SSRIs increase serotonin signaling, and serotonin has an inhibitory effect on ejaculation and, to a lesser degree, erectile function and libido.

Why SSRIs Affect Ejaculation and Sensation, Not Just Erections

The mechanism here is more specific than 'SSRIs cause sexual side effects' — serotonin has a particularly strong inhibitory effect on the ejaculatory reflex arc specifically, which is exactly why delayed ejaculation, not erectile dysfunction, is the single most consistently reported SSRI sexual side effect across the research literature, sometimes severe enough to prevent ejaculation entirely regardless of how aroused or stimulated a man is. This same serotonergic effect is mild enough to interfere with erectile function and general sensation to a lesser, less consistent degree, but the ejaculatory pathway is disproportionately sensitive to serotonin's inhibitory signaling compared to the arousal and erection pathways, which depend more heavily on dopamine and nitric oxide. This asymmetry is actually put to clinical use elsewhere — SSRIs are prescribed off-label specifically to treat premature ejaculation, deliberately exploiting the exact mechanism that becomes an unwanted side effect for men taking them for depression or anxiety instead.

What SSRIs Actually Do Sexually

• •Delayed ejaculation: the most consistently reported effect, sometimes severe enough to prevent ejaculation entirely — directly tied to serotonin's inhibitory role in the ejaculatory reflex [1]
• •Reduced libido: common, likely multifactorial (direct serotonergic effect plus, in some cases, mild prolactin elevation)
• •Erectile difficulty: less consistently reported than delayed ejaculation but documented, particularly with paroxetine [2]
• •Genital numbing or reduced sensation: reported by a meaningful minority, and is the symptom most linked to persistent post-discontinuation cases [3]

Management Options

• •Dose reduction (under medical supervision): sexual side effects are often dose-dependent, and a lower effective dose sometimes resolves the issue without losing therapeutic benefit
• •Switching agents: bupropion and mirtazapine have substantially lower rates of sexual dysfunction and are common switch targets when sexual side effects are intolerable [2]
• •Drug holidays (for some SSRIs with short half-lives, under medical guidance only) timed around sexual activity
• •Adding a PDE5 inhibitor for the erectile component specifically, which has evidence for counteracting SSRI-associated erectile difficulty

Post-SSRI Sexual Dysfunction (PSSD)

A smaller subset of men report sexual side effects (particularly genital numbing) persisting after fully discontinuing the medication — a phenomenon termed post-SSRI sexual dysfunction. It remains under-researched and not fully mechanistically explained, but is increasingly recognized as a real, if uncommon, iatrogenic syndrome rather than dismissed outright [3].

How SSRI Sexual Side Effects Compare Across Drug Classes

Not all antidepressants carry the same sexual-side-effect risk, and understanding the relative landscape is useful context before assuming any change in mood medication automatically means sexual side effects have to be tolerated. SSRIs as a class (paroxetine, sertraline, fluoxetine, escitalopram, citalopram) and SNRIs (venlafaxine, duloxetine) carry the highest rates of treatment-emergent sexual dysfunction, generally in the same broad range regardless of which specific SSRI is used, though paroxetine is sometimes reported as having a somewhat higher relative burden. Bupropion, which works primarily through dopamine and norepinephrine rather than serotonin, has consistently the lowest rate of sexual side effects among commonly prescribed antidepressants and is sometimes even associated with mild libido improvement in some patients. Mirtazapine also carries a comparatively low rate. This is why a switch to one of these alternatives is often the first option explored when SSRI sexual side effects are intolerable and dose reduction hasn't resolved things — though the switch decision always has to weigh differences in efficacy for the specific mood or anxiety condition being treated, not sexual side-effect profile alone.

Why PSSD Is Genuinely Difficult to Research

Healy et al.'s work on post-SSRI sexual dysfunction highlights why this specific syndrome has been slow to gain full recognition and study, despite growing patient-reported evidence. Establishing a clear causal link is genuinely hard: depression and anxiety themselves can independently affect sexual function even after successful treatment, making it difficult to cleanly separate a lingering effect of the medication from an unrelated or coincidental persistence of the original condition's sexual symptoms. The relative rarity of clearly documented cases (compared to the much higher prevalence of sexual side effects during active treatment) has also limited the sample sizes available for rigorous study. What is increasingly accepted, even amid this research difficulty, is that PSSD represents a real, distinct clinical phenomenon for at least a subset of affected men — the genital numbness pattern specifically is considered the most distinctive and least explainable-by-other-causes symptom, lending credibility to it as a genuine, medication-linked persistent effect rather than simply unresolved depression.

What to Discuss With a Prescriber if You're Worried About This

If PSSD risk is a significant concern before starting an SSRI, it's a reasonable topic to raise directly with a prescriber — asking about lower-risk alternatives (bupropion, mirtazapine), discussing the plan for monitoring and adjusting if sexual side effects appear, and understanding that early reporting of symptoms during treatment (rather than waiting) gives the most options for dose adjustment or switching before any potential lasting effect has a chance to develop. This isn't a reason to avoid necessary depression or anxiety treatment — untreated depression carries its own serious risks — but an informed conversation about the full risk picture, including this less-discussed possibility, is a reasonable part of shared decision-making before starting treatment.

Tracking Symptoms Alongside Medication Changes

Logging libido, erectile function, and ejaculatory changes on the mancore dashboard alongside medication start dates and dose changes creates the clearest evidence for a conversation with your prescriber — far more useful than recalling timing from memory months later.

The Bottom Line

SSRI sexual side effects are common, mechanistically understood, and manageable through dose adjustment or switching agents — they are not something to silently tolerate or attribute entirely to the underlying mental health condition without discussing options with a prescriber.